ARA-290 Improves Neuropathic Pain and Promotes Nerve Fiber Regeneration

ARA-290 is one of the few compounds with human data showing actual nerve fiber regeneration, not just symptom masking. Small fiber neuropathy—damage to the tiny nerve endings responsible for pain and temperature sensation—is notoriously difficult to treat and often progressive. ARA-290 works through the innate repair receptor (IRR), activating tissue-protective pathways without the hematopoietic side effects of erythropoietin (EPO), from which it was derived. What makes this exciting is the dual outcome: subjective pain improvement and objective evidence of nerve regrowth. For those researching peripheral neuropathy, chronic pain, or nerve injury, this suggests ARA-290 may help the nervous system rebuild damaged structures, not just reduce inflammation. The mechanism—activating cellular repair pathways—has implications beyond neuropathy for any condition involving tissue damage and regeneration.

ARA-290 (also called Cibinetide) is a synthetic peptide derived from erythropoietin (EPO) that selectively activates the innate repair receptor without stimulating red blood cell production. This was a breakthrough because EPO's tissue-protective effects were known, but its hematopoietic activity (increasing red blood cells) limited its use outside of anemia. ARA-290 isolates the repair signaling without the blood cell stimulation. This 2015 trial used corneal confocal microscopy—a non-invasive technique that directly visualizes small nerve fibers—providing objective proof of nerve regeneration rather than relying solely on subjective pain scales. The study focused on sarcoidosis patients because they have well-characterized small fiber neuropathy, but the underlying pathology (axonal degeneration, loss of intraepidermal nerve fibers) is similar across many neuropathy causes including diabetes, chemotherapy, and autoimmune conditions. ARA-290 advanced to Phase III trials but faced development challenges; however, the human data established clear proof of concept for nerve repair.

ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density